Organigram Holdings Inc. (TSE:OGI - Free Report) - Stock analysts at Atb Cap Markets decreased their FY2025 earnings per share (EPS) estimates for shares of Organigram in a report released on Monday, December 16th. Atb Cap Markets analyst F. Gomes now anticipates that the company will post earnings of ($0.13) per share for the year, down from their previous estimate of ($0.12). The consensus estimate for Organigram's current full-year earnings is $0.16 per share.
Other equities analysts have also recently issued reports about the stock. Canaccord Genuity Group dropped their price target on shares of Organigram from C$3.60 to C$3.15 and set a "speculative buy" rating for the company in a research note on Monday, December 9th. ATB Capital cut their target price on Organigram from C$5.25 to C$3.50 in a research note on Tuesday.
Get Our Latest Stock Analysis on OGI
Organigram Trading Down 0.5 %
TSE OGI traded down C$0.01 on Thursday, hitting C$2.09. 173,364 shares of the stock were exchanged, compared to its average volume of 296,019. Organigram has a 52-week low of C$1.61 and a 52-week high of C$3.95. The firm has a market capitalization of C$226.91 million, a P/E ratio of -0.83, a P/E/G ratio of 0.42 and a beta of 1.13. The company has a debt-to-equity ratio of 1.13, a quick ratio of 2.62 and a current ratio of 6.95. The stock has a fifty day moving average price of C$2.26 and a two-hundred day moving average price of C$2.30.
Insider Buying and Selling
In other Organigram news, Senior Officer Paolo De Luca sold 12,014 shares of Organigram stock in a transaction on Thursday, October 24th. The stock was sold at an average price of C$2.52, for a total transaction of C$30,275.28. 31.32% of the stock is currently owned by insiders.
Organigram Company Profile
(
Get Free Report)
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
Read More
Before you consider Organigram, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organigram wasn't on the list.
While Organigram currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.